About Biodesix
Biodesix is a publicly listed company based in Boulder (United States) founded in 2005. Cancer detection diagnostics assays are developed and offered. Biodesix has raised $200.16 million across 25 funding rounds from investors including Lincoln Park Capital. The company has 273 employees. Biodesix has completed 2 acquisitions, including IndiDX and Xpresys Lung. Its chief executive, as recorded, is Scott Hutton. Biodesix offers products and services including Diagnostic Tests and Development Services. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Lung cancer. Its competitors include OncoCyte, Broncus and Riverain Tech; 3 of its 3 listed competitors have raised funding.
Company details
Biodesix was founded in 2005 and is headquartered in Boulder, United States. Diagnostic assays for cancer detection are developed by the company within the healthcare sector. In vitro diagnostic tests are provided, including Nodify Lung, which features two blood-based proteomic tests for assessing malignancy risk in lung nodules, and GeneStrat NGS for broad tumor mutation analysis. Operations focus on advancing precision medicine tools.
- Headquarters Boulder, United States
- Employees 273
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website biodesix.com
- Social LinkedIn X Facebook YouTube
- Legal Name Biodesix, Inc.
- Annual Revenue$88.5 M (USD)24.08as on Dec 31, 2025
- Net Profit-$35.27 M (USD)17.86as on Dec 31, 2025
- EBITDA-$22.16 M (USD)23.05as on Dec 31, 2025
- Total Equity Funding$200.16M (USD)
in 25 rounds
- Latest Funding Round$40.3M (USD), Post-IPO
Nov 2022
- Investors
- Employee Count273
- Investments & AcquisitionsIndiDX
& 1 more
Products & Services of Biodesix
Biodesix offers a comprehensive portfolio of products and services, including Diagnostic Tests and Development Services.
Tests for lung cancer detection and personalized treatment guidance
Custom services for diagnostic tools and therapeutics development
Funding Insights of Biodesix
Biodesix has successfully raised a total of $200.16M across 25 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40.3 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $200.16M
- Total Rounds 25
- Last Round Post-IPO — $40.3M
- First Round $10M
(Sep 2009)
- Investors Count 1
Latest 10 of 25 funding rounds of Biodesix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $40.3M | Post-IPO | – | – | – |
| Apr 2022 | $11.7M | Post-IPO | – | – | – |
| Mar 2022 | Post-IPO | – | – | ||
| Dec 2019 | $3.04M | Series F | – | – | – |
| Aug 2019 | $4.9M | Series F | – | – | – |
| Oct 2018 | $17.51M | Series F | – | – | – |
| Jun 2018 | $7.99M | Series F | – | – | – |
| May 2018 | $5.2M | Series F | – | – | – |
| Feb 2018 | $1.5M | Series F | – | – | – |
| Apr 2017 | $13.17M | Series F | – | – | – |
1 investors in total: 1 institutional.
Investors in Biodesix
Biodesix has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Lincoln Park Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward North American opportunities. | lpcfunds.com | Chicago, United States |
Investor details for Biodesix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biodesix
56 people are tracked at Biodesix (32 in leadership, 8 in board & advisors, 16 in team); the tracked headcount is 273.
| Name | Role | Group |
|---|---|---|
Scott Hutton | CEO | Leadership |
Laura Peek | Vice President, Laboratory Operations - De Soto | Leadership |
Brianna Phillips | VP, Quality & Regulatory Affairs | Leadership |
Niki Givens | VP, Clinical Research | Leadership |
Tonya Hill | Senior Director, National Accounts | Leadership |
Richard Vogel | National Account Director - Managed Care | Leadership |
Steve Springmeyer | Co-Chief Medical Officer | Leadership |
Kieran O'Kane | Chief Commercial Officer | Leadership |
Robin Harper Cowie | Chief Financial Officer | Leadership |
Tom Dugan | Senior Director Market Access | Leadership |
Gary Pestano | Chief Development Officer | Leadership |
Jessica Olbricht | Senior Director of Human Resources | Leadership |
Michael F. Sweeney | Director, Business Development Operations | Leadership |
Shaji Thomas | Regional Sales Director | Leadership |
Natalie st. Denis | Director, Corporate Marketing & Communications | Leadership |
Brittany D'Alessio | Director Of Laboratory Operations | Leadership |
Timothy Dupont | Vice President, Strategic And Commercial Operations | Leadership |
Chris Watkins | Director Of Information Technology | Leadership |
Emily Mortimer | National Director, Market Access | Leadership |
Kevin Prophete | Senior Director Of National Accounts - Oncology | Leadership |
36 more people are available in the full profile.
Complete people profiles for Biodesix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Biodesix
Biodesix is a publicly listed company on the NASDAQ with ticker symbol BDSX in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Oct 2020
- Listed onNASDAQ: BDSX
- Listed entityBiodesix, Inc.
- Exchange sectorHealth services
- ISINUS09075X2071
- Share price$25.00 (-2.72% on the day) · 2026-10-13
- Market capitalisation$263.8M
- EPS (diluted, trailing year)$-3.17
- Volume (last session)53,317
Financials of Biodesix
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $88.5M | -$35.3M | -$22.2M |
| 2024 | $71.3M | -$42.9M | -$28.8M |
| 2023 | $49.1M | -$52.1M | -$35.8M |
| 2022 | $38.2M | -$65.5M | -$46.9M |
| 2021 | $54.5M | -$43.2M | -$36.1M |
Detailed financial statements for Biodesix
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biodesix
Biodesix has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include IndiDX and Xpresys Lung.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proteomics-based liquid biopsy for lung cancer is provided. | xpresyslung.com | Boulder, United States | 2013 | Jul 2018 | •••• | |
Blood-based diagnostics for oncology. | indidx.com | Boulder, United States | 2005 | Jul 2018 | •••• |
Complete acquisition details for Biodesix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Biodesix
6 dated milestones of Biodesix across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Biodesix is founded.
- Funding First funding round of $10.0M.
- Acquisition Acquires IndiDX.
- Acquisition Acquires Xpresys Lung.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $40.3M.
Competitors of Biodesix
Biodesix has 3 listed competitors in our database, 3 of them funded. They include OncoCyte, Broncus and Riverain Tech.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| oncocyte.com | 2009 | Irvine, United States | $15.35M | 76 | Non-invasive diagnostic test solutions for cancer treatment are developed. | |
| broncus.com | 1997 | San Jose, United States | $44.5M | 36 | Minimally invasive technologies for lung disease treatment are developed. | |
| riveraintech.com | 2008 | Miamisburg, United States | $15M | 25 | Software tools are developed for early lung disease detection. |
Detailed competitors of Biodesix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Biodesix
The website of Biodesix (biodesix.com) receives about 7.4K visits a month and ranks #2,413,737 among all websites worldwide, #3,304 in Biotechnology and Pharmaceuticals.
- Monthly visits7.4K
▼ 1.8% vs previous month
- Unique visitors3.8K
per month
- Global rank#2,413,737
among all websites
- Category rank#3,304
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit2.6
- Average visit2 min 21 sec
- DevicesDesktop 49% · Mobile 51%
Websites whose visitors overlap most with Biodesix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| aveooncology.com | 100% | 5.3K | #4,236,239 | View details | |
| foundationmedicine.com | 96% | 65K | #611,310 | View details | |
| novocure.com | 96% | 37.8K | #872,540 | View details | |
triconference.com | triconference.com | 95% | #1,678,419 | – | |
nextgenerationdx.com | nextgenerationdx.com | 94% | #3,909,208 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Biodesix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Biodesix (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biodesix
Complete news archive for Biodesix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biodesix
Biodesix was founded in 2005 and raised its 1st funding round 4 years after it was founded.
Biodesix is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Scott Hutton is the CEO of Biodesix, as recorded in our data.
Biodesix is a funded company, having raised a total of $200.16M across 25 funding rounds to date. The company's 1st funding round was a Series F of $13.17M, raised on Sep 2009.
Biodesix has 273 employees.
Annual revenue of Biodesix is $88.5M as on Dec 31, 2025.
Biodesix was founded in 2005 and is headquartered in Boulder, United States. Diagnostic assays for cancer detection are developed by the company within the healthcare sector. In vitro diagnostic tests are provided, including Nodify Lung, which features two blood-based proteomic tests for assessing malignancy risk in lung nodules, and GeneStrat NGS for broad tumor mutation analysis. Operations focus on advancing precision medicine tools.
Biodesix's top competitors include OncoCyte, Riverain Tech and Broncus.
Biodesix offers Diagnostic Tests and Development Services.
Yes, Biodesix is publicly traded on NASDAQ under the ticker symbol BDSX.
Biodesix has made 2 acquisitions, including IndiDX, and Xpresys Lung.
Biodesix has 1 investor. Key investors include Lincoln Park Capital.